^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive Non-Small Cell Lung Cancer
Excerpt:
...Patients with primary non-small cell lung cancer with 2 common EGFR mutations（EGFR 19 Del or 21 L858R）; 6. ...
Trial ID:
Source:
Title:
97P - Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I-III non-small cell lung cancer with high-risk pathological factors
Published date:
03/23/2023
Excerpt:
Patients underwent completely resected pathologic stage I–III lung adenocarcinoma...Patients were assigned to aumolertinib group (group A): patients with EGFR mutation-positive (exon 19 deletion or L858R) received aumolertinib...At data cut-off, all patients in aumolertinib group have no symptoms of tumor recurrence and continued aumolertinib, the 1-year DFS was 100%. In group B, 64% patients were alive and disease-free...This is the first report that aumolertinib has efficacy in patients with completely resected stage I-III EGFR mutated NSCLC with high-risk pathological factors.
Source:
Title:
A Case of Brain Metastases from Lung Cancer with Epilepsy and ECOG Score of 4 Successfully Treated with Aumolertinib
Published date:
08/08/2023
Excerpt:
In this case, we reported a right lung adenocarcinoma cT3N3M1 patient with brain metastasis, malignant pleural effusion, and a positive EGFR 19del mutation who obtained a remarkable curative effect and good tolerance, after treatment with aumolertinib.
Source:
Title:
Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases
Published date:
08/08/2023
Excerpt:
Herein, we present an EGFR-mutated NSCLC patient with brain metastases currently demonstrating exceptional durability in response to 165mg high-dose aumolertinib after local progression was observed with a standard dose….A 46-year-old female was diagnosed with stage IVB (cT4N2M1c) lung adenocarcinoma with multiple pulmonary nodules, right malignant pleural effusion and brain metastases. While awaiting next-generation sequencing (NGS) results, the patient received intra-pleural injection of Endostar (45mg on Day 1, 4, and 7) and cisplatin (30mg on Day 2 and 5), as well as one cycle of pemetrexed chemotherapy. Upon confirmation of EGFR exon 19 deletion mutation, the patient was started with standard dose aumolertinib (110mg daily). The patient demonstrated excellent overall response including partial response (PR) in lung lesions and complete response (CR) in multiple brain metastases after 2 months treatment of aumolertinib. Local progression of the primary lung lesion occurred 17 months later with 110mg aumolertinib administration, but brain lesions continued CR on MRI brain....The patient is demonstrating a durable response of over 33 months to aumolertinib and tolerating the high-dose treatment very well with no significant adverse events.
Source:
Title:
Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment
Published date:
08/08/2023
Excerpt:
We report a clinical case of female lung cancer patient with brain metastasis and giant lung lesion...A 36-year-old female patient was diagnosed with right upper lobe adenocarcinoma...Further lung tumor biopsy genetic testing showed EGFR exon 19 deletion mutation….Then the primary tumor lesion shrank obviously, the patient received aumolertinib 110 mg per day as maintenance treatment. So far, primary tumor and intracranial metastatic lesions have remained completely remission, and the progression-free survival has exceeded 36 months....This case demonstrated that aumolertinib combined with synchronous upfront cranial and thoracic radiotherapy have significant antitumor activity and excellent safety.
Source:
Title:
Intracranial Complete Remissions and Long-Term Response in a EGFR positive NSCLC Patient with Brain Metastases: Case Report
Published date:
08/08/2023
Excerpt:
This case report presents an advanced lung adenocarcinoma patient with brain metastases treated with aumolertinib…The imaging and tissue analysis revealed stage IVB (cT4N0M1c) NSCLC with brain metastases. Gene tests showed EGFR 19del… We reported a patient with EGFR-mutant NSCLC with brain metastases who benefited from aumolertinib more than 33 months and have surprising intracranial efficacy as CR. In this case, aumolertinib proved to be a highly effective and well-tolerated treatment option for NSCLC with brain metastases.
